Tebonin Forte

Each film-coated tablet contains: Dried, purified extract (EGb 761) from Ginkgo biloba leaves (50:1) 120 mg, standardized to a content of 24% Ginkgo flavone glycosides and 6% terpene lactones.

Neurotropic agent.
Pharmacology: Properties: Based on a complicated patented manufacturing process, Ginkgo biloba EGb 761 (Tebonin Forte) contains enriched active ingredients obtained from leaves of the Ginkgo tree. Ginkgo biloba EGb 761 (Tebonin Forte) improves the flow properties of the blood and increases its flow rate, particularly the region of small and very small blood vessel. Both in the brain as well as in the arms and legs. Ginkgo biloba EGb 761 (Tebonin Forte) produces an improvement in the supply of blood and oxygen to the tissue and protects tissue cells from the damaging effects of lack in oxygen.
In case of disturbances of cerebral performance, Ginkgo biloba EGb 761 (Tebonin Forte) improves decreasing intellectual capacity and vigilance, thus providing relief to accompanying symptoms such as dizziness, tinnitus, headache, deficient memory and emotional instability with anxiety.
Ginkgo biloba EGb 761 (Tebonin Forte) increases hearing capacity in case of cervical syndrome.
Ginkgo biloba EGb 761 (Tebonin Forte) produces a reduction in pain and unpleasant sensations with formication as well as a sensation of numbness and coldness accompanying circulatory disturbances in the limbs. In the case of intermittent claudication (walking pains) Ginkgo biloba EGb 761 (Tebonin Forte) clearly extends the pain-free walking distance.
Ginkgo biloba EGb 761 (Tebonin Forte) has no unfavourable influence on the carbohydrate metabolism and is therefore also suitable for diabetics.

For the treatment of disturbance in cerebral performance (decreasing intellectual capacity and vigilance) with the following symptoms: dizziness, tinnitus, headache, deficient memory, emotional instability with anxiety.
As supporting treatment for restricted hearing capacity due to cervical syndrome. For the treatment of peripheral arterial circulatory disturbance with maintenance of circulatory reserve (intermittent claudication).
For the symptomatic treatment of mental losses due to organic brain syndrome within the framework of a general therapeutic concept for dementia syndrome having as major symptoms: deficient memory, disturbances of concentration, depressive mood, dizziness, tinnitus, headache.
For the symptomatic treatment of mild cognitive impairment (MCI).

Dementia syndrome, Mild Cognitive Impairment (MCI): Adults from 18 years on take 1 film-coated tablet (corresponding to 120 mg Ginkgo extract) 2 times per day.
Peripheral arterial occlusive disease, vertigo, adjuvant tinnitus treatment: Adults from 18 years on take 1 film-coated tablet (corresponding to 120 mg Ginkgo extract) 1 to 2 times per day.
Duration: The treatment duration should be at least 8 weeks. If no improvement occurs after 3 months of treatment, or if the pathological symptoms get worse, consult the doctor.

Do not take Ginkgo biloba EGb 761 (Tebonin Forte): If the patient is allergic (hypersensitive) to Gingko biloba or to any of the other ingredients of Ginkgo biloba EGb 761 (Tebonin Forte).
During pregnancy. There are no or limited amount of data from the use of Ginkgo biloba EGb 761 (Tebonin Forte) in pregnant women. As a precautionary measure, it is preferable to avoid the use of Ginkgo biloba EGb 761 (Tebonin Forte).
As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in human milk.
Animal studies do not reveal harmful effects of Ginkgo biloba EGb 761 (Tebonin Forte) on the fertility.

Do not take Ginkgo biloba EGb 761 (Tebonin Forte): During pregnancy. There are no or limited amount of data from the use of Ginkgo biloba EGb 761 (Tebonin Forte) in pregnant women. As a precautionary measure, it is preferable to avoid the use of Ginkgo biloba EGb 761 (Tebonin Forte).
As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in human milk.
Animal studies do not reveal harmful effects of Ginkgo biloba EGb 761 (Tebonin Forte) on the fertility.

There are no verified data on the frequency of the undesirable effects observed during treatment with Ginkgo biloba-containing preparations, since these undesirable effects have become known through single reports from patients, physicians or pharmacists. According to these reports, the following undesirable effects may occur during treatment with Ginkgo biloba EGb 761 (Tebonin Forte): Gastrointestinal disorders: Mild gastrointestinal disturbances.
Skin and subcutaneous tissue disorders/Immune system disorders: Hypersensitivity reactions.
Nervous system disorders: Headache.
Vascular disorders: Bleeding from single organs has been reported.

Interactions with other drugs: In case of simultaneous application of Ginkgo biloba EGb 761 (Tebonin Forte) with coagulation-inhibiting drugs (such as phenprocoumon, warfarin, clopidogrel, acetylsalicylic acid and other non-steroidal antirheumatics) it cannot be excluded that the effect of these medicines is enhanced.
As for all the medicinal preparations, it cannot be excluded Ginkgo biloba EGb 761 (Tebonin Forte) acts on the metabolization of different other medicinal preparations which may influence the potency and/or duration of the effect of the preparation concerned. There are not sufficient investigations available on these effects. Tell the doctor or pharmacist if the patient is taking or has recently taken any other medicines, including medicines obtained without a prescription.

Store at temperatures not exceeding 30°C.

Peripheral Vasodilators & Cerebral Activators

N06DX02 - Ginkgo folium ; Belongs to the class of other anti-dementia drugs.

Rx